307 related articles for article (PubMed ID: 23475532)
1. Combined flow cytometric assessment of CD45, HLA-DR, CD34, and CD117 expression is a useful approach for reliable quantification of blast cells in myelodysplastic syndromes.
Sandes AF; Kerbauy DM; Matarraz S; Chauffaille Mde L; López A; Orfao A; Yamamoto M
Cytometry B Clin Cytom; 2013 May; 84(3):157-66. PubMed ID: 23475532
[TBL] [Abstract][Full Text] [Related]
2. Multicenter comparison of CD34+ myeloid cell count by flow cytometry in low-risk myelodysplastic syndrome. Is it feasible?
Font P; Subirá D; Matarraz S; Benavente C; Cedena MT; Morado M; Pérez Corral A; Bellón JM; Díez-Martín JL
Cytometry B Clin Cytom; 2018 May; 94(3):527-535. PubMed ID: 28618451
[TBL] [Abstract][Full Text] [Related]
3. [Four-color flow cytometric immunophenotypic features of blasts in myelodysplastic syndromes].
Wu YJ; Li JY; Qiu HR; Xiao B; Zhang JF; Song JH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Feb; 14(1):50-3. PubMed ID: 16584591
[TBL] [Abstract][Full Text] [Related]
4. Detection of molecular targets on the surface of CD34+CD38- bone marrow cells in myelodysplastic syndromes.
Xie W; Wang X; Du W; Liu W; Qin X; Huang S
Cytometry A; 2010 Sep; 77(9):840-8. PubMed ID: 20662087
[TBL] [Abstract][Full Text] [Related]
5. Analysis of immunohistochemical markers in bone marrow sections to evaluate for myelodysplastic syndromes and acute myeloid leukemias.
Dunphy CH; O'Malley DP; Perkins SL; Chang CC
Appl Immunohistochem Mol Morphol; 2007 Jun; 15(2):154-9. PubMed ID: 17525626
[TBL] [Abstract][Full Text] [Related]
6. Thy-1 (CDw90) and c-kit receptor (CD117) expression on CD34+ hematopoietic progenitor cells: a five dimensional flow cytometric study.
D'Arena G; Musto P; Cascavilla N; Carotenuto M
Haematologica; 1998 Jul; 83(7):587-92. PubMed ID: 9718862
[TBL] [Abstract][Full Text] [Related]
7. CD34/CD117 positivity in assessment of prognosis in children with myelodysplastic syndrome.
Tavil B; Cetin M; Tuncer M
Leuk Res; 2006 Feb; 30(2):222-4. PubMed ID: 16098587
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic potential of CD34+ cell antigen expression in myelodysplastic syndromes.
De Smet D; Trullemans F; Jochmans K; Renmans W; Smet L; Heylen O; Bael AM; Schots R; Leus B; De Waele M
Am J Clin Pathol; 2012 Nov; 138(5):732-43. PubMed ID: 23086775
[TBL] [Abstract][Full Text] [Related]
9. Bone marrow cells from myelodysplastic syndromes show altered immunophenotypic profiles that may contribute to the diagnosis and prognostic stratification of the disease: a pilot study on a series of 56 patients.
Matarraz S; López A; Barrena S; Fernandez C; Jensen E; Flores-Montero J; Rasillo A; Sayagues JM; Sánchez ML; Bárcena P; Hernandez-Rivas JM; Salvador C; Fernandez-Mosteirín N; Giralt M; Perdiguer L; Laranjeira P; Paiva A; Orfao A
Cytometry B Clin Cytom; 2010 May; 78(3):154-68. PubMed ID: 20198685
[TBL] [Abstract][Full Text] [Related]
10. Flow cytometric scoring system (FCMSS) assisted diagnosis of myelodysplastic syndromes (MDS) and the biological significance of FCMSS-based immunophenotypes.
Xu F; Li X; Wu L; He Q; Zhang Z; Chang C
Br J Haematol; 2010 May; 149(4):587-97. PubMed ID: 20331463
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical properties of bone marrow mast cells in systemic mastocytosis: evidence for expression of CD2, CD117/Kit, and bcl-x(L).
Jordan JH; Walchshofer S; Jurecka W; Mosberger I; Sperr WR; Wolff K; Chott A; Bühring HJ; Lechner K; Horny HP; Valent P
Hum Pathol; 2001 May; 32(5):545-52. PubMed ID: 11381374
[TBL] [Abstract][Full Text] [Related]
12. Advanced pediatric myelodysplastic syndromes: can immunophenotypic characterization of blast cells be a diagnostic and prognostic tool?
Veltroni M; Sainati L; Zecca M; Fenu S; Tridello G; Testi AM; Merlone AD; Buldini B; Leszl A; Lo Nigro L; Longoni D; Bernini G; Basso G;
Pediatr Blood Cancer; 2009 Mar; 52(3):357-63. PubMed ID: 19061215
[TBL] [Abstract][Full Text] [Related]
13. Improving the differential diagnosis between myelodysplastic syndromes and reactive peripheral cytopenias by multiparametric flow cytometry: the role of B-cell precursors.
Reis-Alves SC; Traina F; Metze K; Lorand-Metze I
Diagn Pathol; 2015 Apr; 10():44. PubMed ID: 25924846
[TBL] [Abstract][Full Text] [Related]
14. Immunophenotypic characterization of myelopoiesis in early and late myelodysplastic syndromes: use of CD44 as an aid in early diagnosis.
Karmon Y; Manaster J; Chezar J
Cytometry; 2002 Aug; 50(4):225-30. PubMed ID: 12210602
[TBL] [Abstract][Full Text] [Related]
15. [Analysis of immunophenotype and leukemia associated immunophenotype in 610 patients with acute myeloid leukemia].
Liu YR; Wang YZ; Chen SS; Chang Y; Fu JY; Li LD; Wang H; Yu H; Jiang B; Huang XJ
Zhonghua Xue Ye Xue Za Zhi; 2007 Nov; 28(11):731-6. PubMed ID: 18457262
[TBL] [Abstract][Full Text] [Related]
16. Prognostic relevance of the flow cytometric count of medullar blasts in myelodysplastic syndromes.
Molteni A; Riva M; Cesana C; Speziale V; Nichelatti M; Scarpati B; Greco R; Ravano E; Cairoli R; Rossini S; Morra E
Eur J Haematol; 2015 Jun; 94(6):519-25. PubMed ID: 25307971
[TBL] [Abstract][Full Text] [Related]
17. [Diagnostic significance of immunophenotyping of bone marrow cells in myelodysplastic syndrome without an increase of marrow blasts].
Xu J; Zhang W; Liu Y; Wan SG; Sun XJ; Zhao H
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Dec; 17(6):1477-81. PubMed ID: 20030930
[TBL] [Abstract][Full Text] [Related]
18. Bone marrow trephine findings in acute myeloid leukaemia with multilineage dysplasia.
Ngo N; Lampert IA; Naresh KN
Br J Haematol; 2008 Feb; 140(3):279-86. PubMed ID: 17973948
[TBL] [Abstract][Full Text] [Related]
19. Prognostic relevance of cytometric quantitative assessment in patients with myelodysplastic syndromes.
Falco P; Levis A; Stacchini A; Ciriello MM; Geuna M; Notari P; Omedè P; Pautasso M; Prato G; Strola G; Gioia D; Bonferroni M; Cametti G; Ferrero D; Freilone R; Gaidano G; Marinone C; Marmont F; Pollio B; Salvi F; Saglio G; Girotto M;
Eur J Haematol; 2011 Nov; 87(5):409-18. PubMed ID: 21711395
[TBL] [Abstract][Full Text] [Related]
20. Clinical impact of leukemic blast heterogeneity at diagnosis in cytogenetic intermediate-risk acute myeloid leukemia.
Hoffmann MH; Klausen TW; Boegsted M; Larsen SF; Schmitz A; Leinoe EB; Schmiegelow K; Hasle H; Bergmann OJ; Sorensen S; Nyegaard M; Dybkaer K; Johnsen HE
Cytometry B Clin Cytom; 2012 May; 82(3):123-31. PubMed ID: 22328535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]